



## Product Information

Product ID I5210

CAS No. 941678-49-5

Chemical Name

Synonym Ruxolitinib

Formula  $C_{17}H_{18}N_6$

Formula Wt. 306.37

Melting Point

Purity  $\geq 98\%$

Solubility DMSO 61 mg/mL (199.1 mM)


Ethanol 61 mg/mL (199.1 mM)

Water Insoluble

Store Temp  $-20^{\circ}\text{C}$

Ship Temp Ambient

**Description** INCB018424 is an inhibitor of JAK1/2 that is clinically used to treat rheumatoid arthritis and myelofibrosis. INCB018424 exhibits anticancer, anti-inflammatory, and antiviral activities. In myeloma cells, INCB018424 inhibits cell growth. INCB018424 also inhibits in vitro infection by HIV-1, HIV-2, and SHIV by preventing viral replication in lymphocytes. In animal models of CCL4-induced hepatic injury, INCB018424 prevents inflammation by decreasing neutrophil and macrophage infiltration, suppressing activation of NF- $\kappa$ B, and limiting release of TNF- $\alpha$ , IL-10, and IL-1 $\beta$ . TEST!!!!!!



## Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
I5210	5 mg	\$71.90
I5210	25 mg	\$235.40
I5210	50 mg	\$365.50

**References** Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. *Blood*. 2014 Dec 18;124(26):3924-31. PMID: 25352124.

Hazem SH, Shaker ME, Ashamallah SA, et al. The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. *Chem Biol Interact*. 2014 Sep 5;220:116-27. PMID: 24973641.

Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. *Antimicrob Agents Chemother*. 2014;58(4):1977-86. PMID: 24419350.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.